FORT WASHINGTON, Pa, December 18, 2007 – Verilogue, inventor and leader of new technology for Point of Practice™ pharmaceutical market research, announces plans for leveraging its $4 million in financing from Edison Venture Fund of Lawrenceville, NJ.
Verilogues patent-pending technology system captures real-time physician-patient conversations at the Point of Practice™. The companys large, nationwide database of recorded interactions provides feedback on specific medicines, competitive positioning and communication materials for pharmaceutical and biotech companies.
“Our due diligence identified brand managers who raved about Verilogues unique research techniques and insightful analysis,” stated Orlando Mendoza of Edison Venture Fund. “We were impressed by how quickly Verilogue has executed and ramped up,” added John Martinson, managing partner of Edison Venture Fund.
“Our plans for the financing include advancing our technology platform and nationwide database of physician-patient information,” remarked Jeff Kozloff, president and CEO for Verilogue. “We embark on an exciting time for medical market research. By using Verilogues technology to improve access and information sharing, healthcare companies are now equipped with more reliable customer data to enhance disease research, drug development and communication methods.”
Verilogue also plans to utilize the funds for growth in marketing and sales.